论文部分内容阅读
目的 探讨甲胎蛋白 (AFP)阴性的肝细胞癌患者血清细胞间粘附分子 1(sICAM 1)测定在肝细胞癌诊治中的价值。方法 应用酶联免疫吸附分析法测定 46例AFP阴性肝细胞癌sICAM 1水平及外科治疗前后的改变。结果 46例中 ,AFP中位值 8.6 μg/L ,sICAM 1中位值1146 μg/L ,其中sICAM 1>70 0 μg/L有 36例 (78% ) ,>10 0 0 μg/L有 2 1例 (46 % )。19例外科治疗前后sICAM 1中位数分别是 12 5 8μg/L和 745 μg/L。 19例中 6例术后肿瘤复发 ,确诊时AFP中位值 15 μg/L ,sICAM 112 5 4μg/L。 结论 sICAM 1测定可进一步提高AFP阴性肝细胞癌的诊断率 ,同时可作为疗效判断和复发监测的指标
Objective To investigate the value of serum intercellular adhesion molecule 1 (sICAM 1) in the diagnosis of hepatocellular carcinoma in patients with alpha-fetoprotein (AFP)-negative hepatocellular carcinoma. Methods The levels of sICAM 1 in 46 patients with AFP-negative hepatocellular carcinoma were determined by enzyme-linked immunosorbent assay (ELISA) before and after surgery. Results Among the 46 patients, the median AFP value was 8.6 μg/L and the median sICAM 1 was 1146 μg/L, among which sICAM 1 >70 μg/L was found in 36 patients (78%), and >100 μg/L had 2 One case (46%). The median sICAM 1 before and after surgery was 195.8 μg/L and 745 μg/L, respectively. In 19 cases, 6 cases had recurrence of the tumor. The median AFP was 15 μg/L at the time of diagnosis, and sICAM 112 5 4 μg/L. Conclusion The sICAM 1 assay can further improve the diagnostic rate of AFP-negative hepatocellular carcinoma, and it can be used as an indicator of efficacy assessment and recurrence monitoring.